Trials (Apr 2022)

Aerobic exercise and telomere length in patients with systolic heart failure: protocol study for a randomized controlled trial

  • Leandro T. Franzoni,
  • Eduardo L. Garcia,
  • Stephanie B. Motta,
  • Mabel M. Ahner,
  • Otávio A. Bertoletti,
  • Marco A. L. Saffi,
  • Anderson D. da Silveira,
  • Alexandre A. Pereira,
  • Adamastor H. Pereira,
  • Luiz C. Danzmann,
  • Ricardo Stein

DOI
https://doi.org/10.1186/s13063-022-06257-1
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background Heart failure (HF) with reduced ejection fraction (HFrEF) is a syndrome that leads to fatigue and reduced functional capacity due to disease-related pathophysiological mechanisms. Aerobic exercise (AERO) plays a key role in improving HF outcomes, such as an increase in peak oxygen uptake (VO2peak). In addition, HF promotes cell senescence, which involves reducing telomere length. Several studies have shown that patients with a worse prognosis (i.e., reduced VO2 peak) also have shorter telomeres. However, the effects of AERO on telomere length in patients with HFrEF are still unknown. In an attempt to fill this gap, we designed a study to determine the effects of 16 weeks of aerobic training (32 sessions) on telomere length in HFrEF patients. Methods In this single-center randomized controlled trial, men and women between 50 and 80 years old will be allocated into two different groups: a moderate-intensity aerobic training and a control grouTelomere length, functional capacity, echocardiographic variables, endothelial function, and walking ability will be assessed before and after the 16-week intervention period. Discussion Understanding the role of physical exercise in biological aging in HFrEF patients is relevant. Due to cell senescence, these individuals have shown a shorter telomere length. AERO can delay biological aging according to a balance in oxidative stress through antioxidant action. Positive telomere length results are expected for the aerobic training group. Trial registration ClinicalTrials.gov NCT03856736 . Registered on February 27, 2019

Keywords